Cell clonality on hypereosinophilic syndrome: What pathogenetic role?

Clinical and Experimental Rheumatology

Volumn 25, Issue 1, 2007, Pages 17-22

  Galimberti, Sara ^a   Ciabatti, Elena ^a   Ottimo, Federica ^a   Rossi, Angela ^a   Trombi, Luisa ^a   Carulli, Giovanni ^a   Cervetti, Giulia ^a   Mattii, Letizia ^a   Bianchi, Guiseppina ^b   Petrini, Mario ^a  

^a UNIVERSITY OF PISA   (Italy)

^b UNIVERSITY HOSPITAL OF PISA   (Italy)

Author keywords

FIP1Li; HES; PDGFR ; TCR

Indexed keywords

ALPHA INTERFERON; CD3 ANTIGEN; CD4 ANTIGEN; GAMMA INTERFERON; HYDROXYUREA; IMATINIB; INTERFERON; INTERLEUKIN 2; INTERLEUKIN 4; INTERLEUKIN 5; PEGINTERFERON; PLATELET DERIVED GROWTH FACTOR ALPHA RECEPTOR; PREDNISONE; PROTEIN KINASE LYN; STEROID; T LYMPHOCYTE RECEPTOR; T LYMPHOCYTE RECEPTOR BETA CHAIN; T LYMPHOCYTE RECEPTOR DELTA CHAIN;

ADULT; AGED; ARTICLE; BONE MARROW BIOPSY; CLONAL VARIATION; FEMALE; GENE REARRANGEMENT; HUMAN; HUMAN CELL; HYPEREOSINOPHILIC SYNDROME; IMMUNOPATHOGENESIS; IMMUNOPHENOTYPING; MALE; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; T LYMPHOCYTE;

ADULT; AGED; BIOLOGICAL RESPONSE MODIFIERS; CYTOKINES; EOSINOPHILS; FEMALE; HUMANS; HYPEREOSINOPHILIC SYNDROME; INTERFERON-ALPHA; MALE; MIDDLE AGED; MRNA CLEAVAGE AND POLYADENYLATION FACTORS; ONCOGENE PROTEINS, FUSION; PIPERAZINES; PROTEIN KINASE INHIBITORS; PYRIMIDINES; RECEPTOR, PLATELET-DERIVED GROWTH FACTOR ALPHA; RETROSPECTIVE STUDIES; T-LYMPHOCYTES;

EID: 33947611190     PISSN: 0392856X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (25)

1. CHUSID MJ, DALE DC, WEST BC, WOLFF SM: The hypereosinophilic syndrome: analysis of fourteen cases with review of the literature. Medicine (Baltimore) 1975; 54: 1-27.
2. BAIN B, PIERRE R, IMBERT M, VARDIMAN JW, BRUNNING RD, FLANDRIN G: Chronic eosinophilic leukaemia and the hypereosinophilic syndrome. In: JAFFE ES, HARRIS NL, STEIN H, VARDIMAN JW, eds. World Health Organization Classification of Tumours: Pathology and Genetics of Tumours of Haematopoietic and Lymphoid Tissues. Lyon, France, 2001; IARC Press: 29-31.
3. HELLMICH B, EHLERS S, CSERNOK E, GROSS WL: Update on the pathogenesis of Churg-Strauss syndrome. Clin Exp Rheumatol 2003; 21 (Suppl. 32): S69-77.
4. BAIN BJ: Eosinophilic leukemia and idiopathic hypereosinophilic syndrome are mutually exclusive diagnoses. Blood 2004; 104: 3836-7.
5. GOTLIB J: Molecular classification and pathogenesis of eosinophilic disorders. Acta Haematologic 2005; 114: 7-25.
6. COOLS J, DEANGELO DJ, GOTLIB J et al.: A tyrosine kinase created by fusion of the PDGFRA and FIPIL1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome. N Engl J Med 2003; 348: 1201-14.
7. ROCHE-LESTIENNE C, LEPERS S, SOENEN-CORNU V et al.: Preudhomme C. Molecular characterization of the idiopathic hypereosinophilic syndrome (HES) in 35 French patients with normal conventional cytogenetics. Leukemia 2005; 19: 792-8.
8. RAGHAVACHAR A, FLEISCHER S, FRICKHOFEN N, HEIMPEL H, FLEISCHER B: T lymphocyte control of human eosinophilic granulopoiesis. Clonal analysis in an idiopathic hypereosinophilic syndrome. J Immunol 1987; 139: 3753-8.
9. SIMON HU, YOUSEFI S, DOMMANN-SCHERRER CC et al.: Expansion of cytokine-producing CD4-CD8-T cells associated with abnormal Fas expression and hypereosinophilia. J Exp Med 1996; 183: 1071-82.
10. ROUFOSSE F, SCHANDENE L, SIBILLE C et al.: T-cell receptor-independent activation of clonal Th2 cells associated with chronic hypereosinophilia. Blood 1999; 94: 994-1002.
11. PAZDRAK K, OLSZEWSKA-PAZDRAK B, STAFFORD S, GAROFALO RP, ALAM R: Lyn, Jak2, and Raf-1 kinases are critical for the antiapoptotic effect of interleukin 5, whereas only Raf-1 kinase is essential for eosinophil activation and degranulation. J Exp Med 1998; 188: 421-9.
12. ADACHI T, CHOUDHURY BK, STAFFORD S, SUR S, ALAM R: The differential role of extracellular signal-regulated kinases and p38 mitogen-activated protein kinase in eosinophil functions. J Immunol 2000; 165: 2198-204.
13. BERKI T, DAVID M, BONE B, LOSONCZY H, VASS J, NEMETH P: New diagnostic tool for differentiation of idiopathic hypereosinophilic syndrome (HES) and secondary eosinophilic states. Pathol Oncol Res 2001; 7: 292-7.
14. ROUFOSSE F, COGAN E, GOLDMAN M: Recent advances in pathogenesis and management of hypereosinophilic syndromes. Allergy 2004; 59: 673-89.
15. GALIMBERTI S, BRIZZI F, MAMELI M, PETRINI M: An advantageous method to evaluate IgH rearrangement and its role in minimal residual disease detection. Leuk Res 1999; 23: 921-9.
16. GALIMBERTI S, BENEDETTI E, MORABITO F et al.: Different gamma/delta clones sustain GVM and GVH effects in multiple myeloma patients after non-myeloablative transplantation. Leuk Res 2005; In Press.
17. PARDANANI A, TEFFERI A: Imatinib therapy for hypereosinophilic syndrome and eosinophilia-associated myeloproliferative disorders. Leuk Res 2004; 28 S1: S47-S52
18. MITELMAN F: Catalog of Chromosome Aberrations in Cancer. New York: Wiley-Liss 1994.
19. Van DONGEN JJ, MACINTYRE EA, GABERT JA et al.: Standardized RT PCR analysis of fusion gene transcripts from chromosome aberrations in acute leukemia for detection of minimal residual disease. Report of the BIOMED-1 Concerted Action: investigation of minimal residual disease in acute leukemia. Leukemia 1999; 13: 1901-28.
20. ROUFOSSE F, SCHANDENE L, SIBILLE C et al.: Clonal Th2 lymphocytes in patients with the idiopathic hypereosinophilic syndrome. Br J Haematol 2000; 109: 540-8.
21. SIMON HU, PLOTZ SG, DUMMER R, BLASER K: Abnormal clones of T cells producing interleukin-5 in idiopathic eosinophilia. N Engl J Med 1999; 341: 1112-20.
22. WOERLY G, ROGER N, LOISEAU S, DOMBROWICZ D, CAPRON A, CAPRON M: Expression of CD28 and CD86 by human eosinophils and role in the secretion of type 1 cytokines (interleukin 2 and interferon gamma): inhibition by immunoglobulin a complexes. J Exp Med 1999; 190: 487-95.
23. ROUFOSSE F, COGAN E, GOLDMAN M: Recent advances in pathogenesis and management of hypereosinophilic syndromes. Allergy 2004; 59: 673-89.
24. OCHIAI K, ISHIHARA C, TOMIOKA H: Signal transduction through interferon-gamma receptor on human eosinophils. Int Arch Allergy Immunol 1999; 118: 443-6.
25. BUTTERFIELD JH: Interferon treatment for hypereosinophilic syndromes and systemic mastocytosis. Acta Haematol 2005; 114: 26-40.